Prevalence of geographic atrophy in Germany ... Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3.

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

we haven’t had any therapeutics to target the root cause of geographic atrophy, an advanced form of dry AMD. Pegcetacoplan (Syfovre) is the first FDA-approved drug to slow the progression of GA.

Geographic atrophy is a subtype of advanced age-related ... but several treatments may help slow the progression of the disease and manage its symptoms. These include: Medications: Some new ...

for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). If approved, ACP has the potential to become the first and only GA treatment available in Japan. GA is ...

WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA ... reviewed at the CHMP's October meeting, but ...

treatment with both every-other-month and monthly SYFOVRE slowed GA progression and showed a generally well-tolerated safety profile. The results were published in The Lancet in October 2023.

Learn more at www.astellas.com. 3 Colijn JM, Liefers B, Joachim N, et al. Enlargement of geographic atrophy from first diagnosis to end of life. JAMA Ophthalmol. 2021;139(7):743–750.